{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:27:33Z","timestamp":1786739253320,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Drug-eluting beads transarterial chemoembolization (DEB-TACE) is a newly developed local regional therapy for improving the efficacy and safety of conventional transarterial chemoembolization (cTACE), which is now universally used to treat patients with unresectable liver cancer.Cohort studies, clinical trials, and meta-analysis have shown DEB-TACE to be associated with favorable treatment responses, prolonged survival, and at least similar safety profile when compared with cTACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objectives:<\/jats:title>\n                    <jats:p>This study was to evaluate the short term clinical efficacy, side effects, and risk factors affecting the clinical effectiveness of CalliSpheres drug loaded bead transcatheter arterial chemoembolization (DEB TACE) in the treatment of primary hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A total of 172 consecutive patients with HCC undergoing DEB TACE (loaded with doxorubicin) from January 2017 to December 2018 were prospectively enrolled. Short term local tumor response was evaluated by the modified RECIST criteria. Postoperative complications and liver function disorders were analyzed based on examinations and clinical symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median follow up period was 310 days. Based on the modified response evaluation criteria in solid tumors criteria, objective response rates(complete response [CR] + partial response [PR]) were 78.7%, 71.6%, and 63.2%, and disease control rates(CR + PR + stable disease) were 95.3%, 92.1%, and 85.9% at 2, 4, and 6 months posttreatment, respectively. Multivariate logistic regression analysis showed that nodule number &gt;3, high BCLC stage, no vascular leak, and previous conventional TACE treatment were associated with poor ORR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Postoperation, liver function showed transient changes. Postoperative complications were tolerated and relieved by symptomatic treatment. The average interval of TACE before D TACE was 43 days, compared with 70 days for average interval of DEB TACE. The average hospital stay was 1.87 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>DEB TACE has improved short term efficacy and lower incidence of complications in primary HCC and prolongs the interval of TACE. It significantly increases the ORR, especially in patients with no extra hepatic metastasis pretreatment. DEB usage actually improves treatment efficacy and provides more benefits to patients. KEY WORDS: Drug-loaded bead-transcatheter arterial chemoembolization, hepatocellular carcinoma, microsphere embolization<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1848_20","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T04:17:46Z","timestamp":1625804266000},"page":"733-739","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma"],"prefix":"10.4103","volume":"17","author":[{"given":"Jinpeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20241021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-19-20241021","doi-asserted-by":"crossref","first-page":"844","DOI":"10.4254\/wjh.v6.i12.844","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques","volume":"6","author":"Imai","year":"2014","journal-title":"World J Hepatol"},{"key":"R3-19-20241021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/jcrt.JCRT_101_20","article-title":"Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma","volume":"16","author":"Meng","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R4-19-20241021","first-page":"437","article-title":"Treatment of unresectable cholangiocarcinoma: Conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy","volume":"24","author":"Kuhlmann","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R5-19-20241021","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R6-19-20241021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ejcts\/ezy289","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"55","author":"Sousa-Uva","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"R7-19-20241021","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R8-19-20241021","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3892\/mco.2014.391","article-title":"Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study","volume":"2","author":"Dai","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"R9-19-20241021","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jhep.2012.07.025","article-title":"Response rate and clinical outcome of HCC after first and repeated cTACE performed \u201con demand\u201d","volume":"57","author":"Terzi","year":"2012","journal-title":"J Hepatol"},{"key":"R10-19-20241021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000368142","article-title":"Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update","volume":"87","author":"Kudo","year":"2014","journal-title":"Oncology"},{"key":"R11-19-20241021","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4103\/jcrt.JCRT_850_20","article-title":"TATI modality: A new perspective on the treatment of advanced hepatocellular carcinoma","volume":"16","author":"Li","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R12-19-20241021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5009\/gnl.2013.7.1.89","article-title":"DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: A pilot study","volume":"7","author":"Song","year":"2013","journal-title":"Gut Liver"},{"key":"R13-19-20241021","first-page":"44","article-title":"Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma","volume":"46","author":"Chen","year":"2017","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"R14-19-20241021","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00270-013-0654-7","article-title":"Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma","volume":"37","author":"Kalva","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R15-19-20241021","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/MNM.0000000000000486","article-title":"Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona clinic liver cancer stage B-C hepatocellular cancer patients","volume":"37","author":"Soydal","year":"2016","journal-title":"Nucl Med Commun"},{"key":"R16-19-20241021","first-page":"206","article-title":"Decoding multifocal hepatocellular carcinoma: An opportune pursuit","volume":"4","author":"Baffy","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R17-19-20241021","first-page":"4","article-title":"Multifocal hepatocellular carcinoma: Intrahepatic metastasis or multicentric carcinogenesis?","volume":"3","author":"Feo","year":"2015","journal-title":"Ann Transl Med"},{"key":"R18-19-20241021","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11605-014-2542-0","article-title":"Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma","volume":"18","author":"Goh","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"R19-19-20241021","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00330-016-4488-y","article-title":"Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: Comparison between drug-eluting beads and lipiodol emulsion","volume":"27","author":"Monier","year":"2017","journal-title":"Eur Radiol"},{"key":"R20-19-20241021","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/carcin\/bgt007","article-title":"Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"R21-19-20241021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0284185116648501","article-title":"Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: Comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study","volume":"58","author":"Lee","year":"2017","journal-title":"Acta Radiol"},{"key":"R22-19-20241021","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.3748\/wjg.v22.i40.8853","article-title":"Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma","volume":"22","author":"Nam","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R23-19-20241021","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00270-012-0394-0","article-title":"Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis","volume":"35","author":"Malagari","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R24-19-20241021","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4103\/jcrt.JCRT_801_19","article-title":"Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis","volume":"16","author":"Shen","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"R25-19-20241021","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4103\/jcrt.JCRT_400_19","article-title":"Apatinib for hepatocellular carcinoma","volume":"15","author":"Ni","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R26-19-20241021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/jcrt.JCRT_910_18","article-title":"Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: \u201cA sharp sword\u201d","volume":"15","author":"Li","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R27-19-20241021","first-page":"1377","article-title":"Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol","volume":"27","author":"Recchia","year":"2012","journal-title":"Oncol Rep"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1848_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:15Z","timestamp":1786735635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1848_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1848_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}